Search This Blog

Wednesday, December 28, 2022

Relmada: Seen completing Phase 3 this month

 Study Design

Go to  

Study Type  :Interventional  (Clinical Trial)
Estimated Enrollment  :400 participants
Allocation:Randomized
Intervention Model:Parallel Assignment
Masking:Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:Treatment
Official Title:A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study)
Actual Study Start Date  :March 30, 2021
Estimated Primary Completion Date  :December 2022
Estimated Study Completion Date  :December 2022

https://clinicaltrials.gov/ct2/show/NCT04855747

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.